Table 2 Duration of primary series vaccine effectiveness against VOC

Against SARS-CoV-2 infection

 Alpha

14–90

1

0.130 (0.120, 0.140)

87.0 (86.0, 88.0)

91–180

–

–

–

 > 180

–

–

–

 Gamma

14–90

4

0.538 (0.470, 0.616)

46.2 (38.4, 53.0)

91–180

1

0.579 (0.535, 0.627)

42.1 (37.3, 46.5)

 > 180

–

–

–

 Delta

14–90

5

0.437 (0.309, 0.618)

56.3 (38.2, 69.1)

91–180

5

0.778 (0.637, 0.951)

22.2 (4.9, 36.3)

 > 180

4

0.791 (0.681, 0.919)

20.9 (8.1, 31.9)

 Omicron

14–90

3

0.659 (0.572, 0.760)

34.1 (24.0, 42.8)

91–180

–

–

–

 > 180

3

0.928 (0.883, 0.977)

7.2 (2.3, 11.7)

Against severe COVID-19

 Alpha

14–90

2

0.100 (0.085, 0.117)

90.0 (88.3, 91.5)

91–180

–

–

–

 > 180

–

–

–

 Gamma

14–90

3

0.225 (0.115, 0.439)

77.5 (56.1, 88.5)

91–180

1

0.230 (0.209, 0.253)

77.0 (74.7, 79.1)

 > 180

–

–

–

 Delta

14–90

7

0.213 (0.112, 0.404)

78.7 (59.6, 88.8)

91–180

7

0.438 (0.320, 0.600)

56.2 (40.0, 68.0)

 > 180

4

0.432 (0.290, 0.643)

56.8 (35.7, 71.0)

 Omicron

14–90

3

0.401 (0.299, 0.539)

59.9 (46.1, 70.1)

91–180

–

–

–

 > 180

3

0.355 (0.281, 0.448)

64.5 (55.2, 71.9)